Barinthus Biotherapeutics PLC
BRNS0.739USD
+0.008+1.04%
收盘 12/19, 16:00（美东）报价延迟15分钟
30.17M总市值
亏损市盈率 TTM
关于 Barinthus Biotherapeutics PLC 公司
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Barinthus Biotherapeutics PLC简介
公司代码BRNS
公司名称Barinthus Biotherapeutics PLC
上市日期Apr 30, 2021
CEOEnright (William J)
员工数量105
证券类型Depository Receipt
年结日Apr 30
公司地址Unit 6-10, Zeus Building, Rutherford Avenue
城市DIDCOT
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编OX11 0DF
电话441865818808
网址https://www.barinthusbio.com/
公司代码BRNS
上市日期Apr 30, 2021
CEOEnright (William J)
Barinthus Biotherapeutics PLC公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Oxford Science Enterprises PLC
21.55%
M&G Investment Management Ltd.
12.73%
Cawood (Frank Wayne)
8.29%
Alphabet, Inc.
3.71%
HSG Holding Ltd.
3.48%
其他
50.25%
持股股东
持股股东
占比
Oxford Science Enterprises PLC
21.55%
M&G Investment Management Ltd.
12.73%
Cawood (Frank Wayne)
8.29%
Alphabet, Inc.
3.71%
HSG Holding Ltd.
3.48%
其他
50.25%
股东类型
持股股东
占比
Venture Capital
25.29%
Investment Advisor
17.92%
Individual Investor
13.37%
Endowment Fund
0.30%
Investment Advisor/Hedge Fund
0.29%
Hedge Fund
0.16%
Research Firm
0.05%
其他
42.62%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
31
17.97M
45.74%
--
2025Q3
32
17.97M
45.74%
-38.01K
2025Q2
30
18.01M
46.38%
+65.89K
2025Q1
30
18.02M
46.62%
-782.82K
2024Q4
29
18.00M
46.88%
-589.55K
2024Q3
29
18.59M
48.15%
-228.24K
2024Q2
30
18.82M
49.02%
+214.04K
2024Q1
29
18.61M
49.21%
-561.80K
2023Q4
34
18.63M
49.81%
+1.21K
2023Q3
36
18.62M
50.13%
-140.49K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Oxford Science Enterprises PLC
8.80M
21.55%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.73%
--
--
Jun 30, 2025
Cawood (Frank Wayne)
3.38M
8.29%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.71%
--
--
Jun 30, 2025
HSG Holding Ltd.
1.42M
3.48%
--
--
Jun 30, 2025
Enright (William)
1.24M
3.05%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.57%
--
--
Jun 30, 2025
Lynn (Geoffrey)
638.44K
1.56%
+638.44K
--
Dec 17, 2024
Johns Hopkins University
122.24K
0.3%
--
--
Jun 30, 2025
Robert W. Baird & Co. Inc.
192.46K
0.47%
+100.00K
+108.15%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Barinthus Biotherapeutics PLC的前五大股东是谁？
Barinthus Biotherapeutics PLC 的前五大股东如下：
Oxford Science Enterprises PLC持有股份：8.80M，占总股份比例：21.55%。
M&G Investment Management Ltd.持有股份：5.20M，占总股份比例：12.73%。
Cawood (Frank Wayne)持有股份：3.38M，占总股份比例：8.29%。
Alphabet, Inc.持有股份：1.51M，占总股份比例：3.71%。
HSG Holding Ltd.持有股份：1.42M，占总股份比例：3.48%。
Oxford Science Enterprises PLC持有股份：8.80M，占总股份比例：21.55%。
M&G Investment Management Ltd.持有股份：5.20M，占总股份比例：12.73%。
Cawood (Frank Wayne)持有股份：3.38M，占总股份比例：8.29%。
Alphabet, Inc.持有股份：1.51M，占总股份比例：3.71%。
HSG Holding Ltd.持有股份：1.42M，占总股份比例：3.48%。
Barinthus Biotherapeutics PLC的前三大股东类型是什么？
Barinthus Biotherapeutics PLC 的前三大股东类型分别是：
Oxford Science Enterprises PLC
M&G Investment Management Ltd.
Cawood (Frank Wayne)
Oxford Science Enterprises PLC
M&G Investment Management Ltd.
Cawood (Frank Wayne)
有多少机构持有Barinthus Biotherapeutics PLC(BRNS)的股份？
截至2025Q4，共有31家机构持有Barinthus Biotherapeutics PLC的股份，合计持有的股份价值约为17.97M，占公司总股份的45.74%。与2025Q3相比，机构持股有所增加，增幅为-0.00%。
哪个业务部门对Barinthus Biotherapeutics PLC的收入贡献最大？
在--，--业务部门对Barinthus Biotherapeutics PLC的收入贡献最大，创收--，占总收入的--%。
